Cellectis S.A. Files Form 6-K

Ticker: CLLS · Form: 6-K · Filed: Nov 19, 2025 · CIK: 1627281

Cellectis S.A. 6-K Filing Summary
FieldDetail
CompanyCellectis S.A. (CLLS)
Form Type6-K
Filed DateNov 19, 2025
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, foreign-private-issuer, regulatory-update

TL;DR

Cellectis S.A. filed a standard 6-K report with the SEC on Nov 19, 2025.

AI Summary

Cellectis S.A. filed a Form 6-K on November 19, 2025, reporting as a foreign private issuer. The filing indicates that the company is submitting its report under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. Cellectis S.A. is incorporated in France and its fiscal year ends on December 31.

Why It Matters

This filing is a routine report for foreign private issuers, providing an update on the company's regulatory disclosures to the SEC.

Risk Assessment

Risk Level: low — This filing is a routine administrative report and does not contain new financial or operational information that would typically impact risk.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, providing information that the registrant makes or is required to make public pursuant to the laws of its home country, or is required to file with or submit to any stock exchange on which it has securities listed, or is made or is required to make public by its security holders.

When was this specific Form 6-K filed?

This Form 6-K was filed on November 19, 2025.

What is the company's primary business classification?

Cellectis S.A. is classified under Standard Industrial Classification code 2836, which pertains to Biological Products (No Diagnostic Substances).

Where is Cellectis S.A. headquartered?

Cellectis S.A.'s principal executive office is located at 8, rue de la Croix Jarry, 75013 Paris, France.

Does Cellectis S.A. file annual reports under Form 20-F?

Yes, the filing indicates with a checkmark that Cellectis S.A. files annual reports under cover of Form 20-F.

Filing Stats: 157 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2025-11-19 06:35:03

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Cellectis S.A. (Registrant) Date: November 19, 2025 /s/ Andr Choulika Andr Choulika Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing